🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Krsnaa Diagnostics Limited KRSNAA NSEPHARMA

Healthcare · Diagnostics & Research · India
https://krsnaadiagnostics.com
Company Profile ↓
₹546.00
-32.12% 1Y
Mkt Cap₹1,771.15 Cr
P/E17.68
P/B1.86
Div. Yield0.49%
52W High₹866.20
52W Low₹520.30
Book Value₹302.23
EPS (TTM)₹30.88

Company Overview

Krsnaa Diagnostics Limited provides diagnostic services in India. It offers a range radiology services, including computed tomography scans, magnetic resonance imaging, X-rays, and ultrasound and advanced imaging; pathology services, such as laboratory, and home collection and preventive health; and teleradiology and telepathology services. The company also provides other diagnostics services, such as ophthalmic test, mammography, dental imaging, stress test, dual-energy X-ray absorptiometry scan, and bone mineral density test. It serves individual patients, government clients, corporate clients, hospitals, clinics, private practitioner, and other healthcare providers. Krsnaa Diagnostics Limited was incorporated in 2010 and is based in Pune, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 17.8% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 16.6% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 17.7, below the sector median of 40.0.

Healthy Margins

Operating margin of 15.7% supports profitability.

Recent Developments

  • Mar 2026 Revenue of ₹772.77 Cr (+7.8% YoY); net profit ₹101.43 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +7.8%, earnings +30.7%.
  • 5-Year Trend Long-term compounding — revenue CAGR 16.6%, profit CAGR 17.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:16.63%
1 Year:7.75%

Compounded Profit Growth

5 Years:17.76%
1 Year:30.70%

Stock Price Performance

1 Year:-32.12%
6 Months:-25.34%
3 Months:-11.44%
1 Month:+1.35%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 7% of range
₹520.30 ₹866.20
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)47.74 · Neutral
Price Performance
1M+1.35%
3M-11.44%
6M-25.34%
1Y-32.12%
Valuation vs Sector

P/E of 17.68 is below the sector median of 39.97 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 16.6% over 5 years.
  • Profit CAGR of 17.8% over 5 years.

CONS

  • Trading 37.0% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
17.68
Industry PE
39.97
Forward P/E
12.07
PEG Ratio
-
Book Value
₹302.23
Price to Book
1.86
P/S
2.29
EV/EBITDA
8.41
Dividend Yield
0.49%

Growth (CAGR)

Revenue 5Y
16.63%
Profit 5Y
17.76%
Revenue (YoY)
7.75%
Earnings (YoY)
30.70%

Profitability & Returns

ROCE
10.64%
ROE
10.35%
ROA
5.56%
Profit Margin
13.13%
Op Margin
15.71%
Gross Margin
68.85%
EPS (Latest Qtr)
₹12.70
EPS (TTM)
₹30.88

Balance Sheet & Liquidity

Debt/Equity
0.55
Quick Ratio
2.59
Current Ratio
2.68
Debt
₹534.32 Cr
Total Assets
₹1,823.72 Cr
Current Assets
₹738.34 Cr
Working Capital
₹463.14 Cr

Ownership

Promoter Holding
45.69%
Chg in Prom Hold
-1.06%
FII / Inst Holding
13.52%
Chg in FII Hold
-0.01%

Financial Snapshot

Enterprise Value
₹1,771.15 Cr
Total Revenue (TTM)
₹772.77 Cr
EBITDA
₹255.19 Cr
Free Cash Flow
₹-76.16 Cr
Operating Cash Flow
₹143.10 Cr
Shares Outstanding
₹3.24 Cr
Gross Margin
68.85%
Payout Ratio
8.91%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 KRSNAA Krsnaa Diagnostics Limited NSEPHARMA 546.00 17.68 ₹1,771.15 Cr 0.49% 10.64% 10.35% 16.63% 17.76%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 133.00 Cr140.00 Cr155.00 Cr158.00 Cr166.00 Cr170.00 Cr186.00 Cr175.00 Cr186.08 Cr192.98 Cr205.99 Cr181.20 Cr192.60 Cr
Cost of Revenue --------58.95 Cr62.79 Cr65.14 Cr54.14 Cr58.68 Cr
Gross Profit --------127.12 Cr130.19 Cr140.85 Cr127.06 Cr133.93 Cr
Operating Expenses 99.00 Cr108.00 Cr124.00 Cr121.00 Cr123.00 Cr128.00 Cr137.00 Cr129.00 Cr96.09 Cr100.42 Cr105.28 Cr103.28 Cr101.64 Cr
Operating Income 19.00 Cr15.00 Cr13.00 Cr16.00 Cr26.00 Cr22.00 Cr27.00 Cr22.00 Cr31.03 Cr29.76 Cr35.57 Cr23.79 Cr32.29 Cr
EBITDA 34.00 Cr31.00 Cr32.00 Cr37.00 Cr44.00 Cr43.00 Cr49.00 Cr45.00 Cr57.37 Cr55.35 Cr63.34 Cr50.13 Cr86.37 Cr
Interest Expense 2.00 Cr2.00 Cr3.00 Cr4.00 Cr7.00 Cr5.00 Cr6.00 Cr6.00 Cr6.81 Cr6.30 Cr8.19 Cr7.79 Cr12.08 Cr
Pretax Income 24.00 Cr18.00 Cr13.00 Cr16.00 Cr23.00 Cr23.00 Cr25.00 Cr25.00 Cr28.61 Cr27.42 Cr31.56 Cr19.68 Cr51.70 Cr
Tax Provision 4.80 Cr3.24 Cr2.86 Cr3.04 Cr3.91 Cr5.29 Cr5.75 Cr6.00 Cr7.93 Cr6.90 Cr7.62 Cr4.44 Cr9.98 Cr
Net Income 19.00 Cr15.00 Cr10.00 Cr13.00 Cr19.00 Cr18.00 Cr20.00 Cr19.00 Cr20.68 Cr20.52 Cr23.95 Cr15.25 Cr41.72 Cr
Diluted EPS 6.034.663.344.025.805.556.076.016.286.257.254.6612.70

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2016Mar 2017Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 39.00 Cr61.00 Cr-487.12 Cr619.63 Cr717.16 Cr772.77 Cr
Cost of Revenue ---155.39 Cr206.51 Cr229.94 Cr240.75 Cr
Gross Profit ---331.74 Cr413.12 Cr487.22 Cr532.02 Cr
Operating Expenses 30.00 Cr42.00 Cr-262.50 Cr343.37 Cr385.42 Cr410.61 Cr
Operating Income 3.00 Cr7.00 Cr-69.24 Cr69.75 Cr101.80 Cr121.41 Cr
EBITDA 9.00 Cr19.00 Cr-140.42 Cr158.64 Cr215.66 Cr255.19 Cr
Interest Expense 9.00 Cr9.00 Cr-6.43 Cr14.09 Cr24.65 Cr34.36 Cr
Pretax Income -3.00 Cr0-80.20 Cr70.01 Cr102.69 Cr130.37 Cr
Tax Provision -1.47 Cr0-18.09 Cr13.17 Cr25.08 Cr28.94 Cr
Net Income -5.00 Cr-0-62.11 Cr56.84 Cr77.61 Cr101.43 Cr
Diluted EPS -9.53-0.14-19.2917.3123.5630.88

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2016Mar 2017Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 186.00 Cr192.00 Cr-909.89 Cr1,171.91 Cr1,281.60 Cr1,823.72 Cr
Current Assets ---222.91 Cr421.19 Cr414.47 Cr738.34 Cr
Cash & Equivalents ---22.72 Cr2.38 Cr3.85 Cr30.22 Cr
Inventory ---25.07 Cr35.81 Cr29.48 Cr26.66 Cr
Receivables ---73.10 Cr176.29 Cr277.75 Cr295.51 Cr
Total Liabilities ---171.16 Cr362.11 Cr398.82 Cr843.33 Cr
Current Liabilities ---99.19 Cr281.47 Cr305.39 Cr275.20 Cr
Long Term Debt ---11.00 Cr5.50 Cr18.50 Cr437.14 Cr
Total Debt 131.00 Cr102.00 Cr-32.48 Cr159.79 Cr203.53 Cr534.32 Cr
Total Equity 11.00 Cr11.00 Cr-738.74 Cr809.80 Cr882.77 Cr980.39 Cr
Shares Outstanding ---3.14 Cr3.23 Cr3.23 Cr3.24 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2016Mar 2017Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -23.00 Cr64.00 Cr-76.30 Cr24.34 Cr87.33 Cr143.10 Cr
Investing Cash Flow -47.00 Cr-54.00 Cr--108.89 Cr-128.88 Cr-99.61 Cr-395.99 Cr
Financing Cash Flow 105.00 Cr-41.00 Cr--33.15 Cr84.19 Cr13.75 Cr279.26 Cr
Capital Expenditure -46.00 Cr-54.00 Cr--141.36 Cr-193.89 Cr-126.63 Cr-219.26 Cr
Free Cash Flow -69.00 Cr10.00 Cr--65.06 Cr-169.54 Cr-39.30 Cr-76.16 Cr
Net Change in Cash 36.00 Cr-31.00 Cr--65.73 Cr-20.34 Cr1.47 Cr26.38 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2016Mar 2017Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ---68.1%66.7%67.9%68.8%
Operating Margin % 7.7%11.5%-14.2%11.3%14.2%15.7%
Net Margin % -12.8%-0.0%-12.8%9.2%10.8%13.1%
ROE % -45.5%-0.0%-8.4%7.0%8.8%10.3%
ROCE % ---8.5%7.8%10.4%7.8%

Shareholding Pattern

Insiders
45.69%
Institutions
13.52%
Public Float
24.89%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for KRSNAA

Google News Sun, 08 Feb 2026

Krsnaa Diagnostics Limited Just Missed EPS By 23%: Here's What Analysts Think Will Happen Next - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxQNzA5bEVjcmdQdjlHdXFEVHd1SzVTN240elh6a0MtRFg3M0k2M1hUeTU4U2pyVlpRR3dQS2Q4dlpGRnFadEhBUkQtVl81WEpJSHdzRmhSRHN1eFN5OXN3YlROYXFxNzlqOXBueEhYMzNXTkc2bERoZVVCUUptVzRWTXR0M053Y0pKLTYwOE…

Google News ue, 26 May 2026

Krsnaa Diagnostics Q4 PAT climbs 102% YoY to Rs 42 cr - Business Standard

<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxQcmswUVE0X3NrTUI1ZGFGN3IwdE04QWUxXzhpZ015OXUtR0ZyQk52cGt3SUJDc3ZYM1UxTXFCaUd3YjZaTHdxNUhuNWdIYlpWZ0YzNFVKWjBqNV9hV0k4OWRadzBKeWdiLVJOUm5JQTNhRF84MXNhbmFaWnc4RnAyRFBEdjcxeUJTNTZqOT…

Google News Mon, 10 Nov 2025

Q2 results impact: Graphite India, Epigral shares decline up to 7% on weak earnings, Krsnaa Diagnostics... - Moneycontrol.com

<a href="https://news.google.com/rss/articles/CBMiggJBVV95cUxQdkZDVW5hWlFDTDNFRXN1bDRJZEJwODlBRVFhazNhb3dMaGFKdnIyeWExNFdjR1lHbmttU1NEa1RNOGMxUnZJWFZobjZubWIxQWNKQ01CVTZEdFY3dWlITE4yd3Z0R1JLVGczdVRJWXFrN2dWQVU5OTVFV2htUWMxZUFBd2lETHRJRDdLTk…

Google News Fri, 29 May 2026

Krsnaa Diagnostics FY26 PAT grows 31% to ₹1,014 million - scanx.trade

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxNU2tUZ0lNZ2ZFM3QzRnVsTzhTN0VBQ0U2VEhLaDhGcHlsWHp2Xy1OSWtsck1SaUN4Rzdsa2V2bXVoQUhaN2M3WmZ3dzRHcllBZVBjVVdncTdjQjFmREs1M1B3OElnZVI5Rm01NVMyaTNHWlZ1QlBBaTFvbi1VUWNYTXJmLTFuZWRYSHlOSH…

Google News Mon, 10 Nov 2025

Krsnaa Diagnostics Shares Surge 10% on Record Q2FY26 Profit - HDFC Sky

<a href="https://news.google.com/rss/articles/CBMie0FVX3lxTE1RSDE4QWN6WmY5Wl9FdlQwcXJDakJVT2dRY3pkQmlZTDdYYk0tYndoSjNIRUEteTRuemdVYXJBM1h6U0hCUjlhX2VCaE1ta0RQZjRiTUE0dFd4T3RQdVVRRzYxWUZSNEdLZHRSeXFzaWZvUTlsM05fTHRldw?oc=5" target="_blank">K…

Google News Fri, 07 Nov 2025

Krsnaa Diagnostics Aims for 20%+ Revenue Growth Through Expansion and AI Integration - scanx.trade

<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxQNUxQdzFveERnSGd0Nks2VWYybnhNY2txZzk0UVJwWWxjVWhBVjVMWnZKbkNjakxDa0wtSTZKeFdqbFRnekN5YnhXcEt2WDFWSnRmOU50Uzk4UnFyZExheENhZzlYeXhNWGZWRC04VmIybl9jR1RoYWxxRFR0LTM4MU5HYjVJdDBrb1M1UE…

KRSNAA — Frequently Asked Questions

What is the current share price of Krsnaa Diagnostics Limited (KRSNAA)?

As of 2026-07-15 09:52 IST, Krsnaa Diagnostics Limited (KRSNAA) trades at ₹546.00 on NSE. Its 52-week range is ₹520.30 to ₹866.20.

What is the market capitalisation of KRSNAA?

Krsnaa Diagnostics Limited (KRSNAA) has a market capitalisation of ₹1,771.15 Cr on NSE.

What is the P/E ratio of KRSNAA?

KRSNAA trades at a trailing price-to-earnings (P/E) ratio of 17.68. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 1.86.

Does KRSNAA pay a dividend?

Krsnaa Diagnostics Limited (KRSNAA) currently offers a dividend yield of 0.49%.

What is the return on equity (ROE) of KRSNAA?

KRSNAA has a return on equity (ROE) of 10.35%. Its return on capital employed (ROCE) is 10.64%.

Is KRSNAA a good stock to buy?

This page provides a data-driven analysis of Krsnaa Diagnostics Limited (KRSNAA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space